The Recall Desk
HighFDA (Drugs)·D-0016-2024·Announced 2023-10-11

FDA Recalls Injectable Fentanyl-Bupivacaine Mixture for Lack of Sterility Assurance

Central Admixture Pharmacy Services is recalling fentanyl-bupivacaine injectables due to lack of assurance of sterility. The recalled 250 mL bags were distributed nationwide.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: This is an FDA Class II recall of an injectable medication with unassured sterility. While no illnesses or injuries have been reported, injectable drugs lacking sterility assurance pose significant infection risk. Per the rubric, high-risk hazards without reported illness are classified as High.

Plain-English summary

Central Admixture Pharmacy Services Inc is recalling fentanyl 2 mcg/mL and bupivacaine 0.0625% in 0.9% sodium chloride solution due to lack of assurance of sterility. The product consists of 250 mL bags with lot number 17-275929 and expiration date of October 12, 2023, and was distributed nationwide in the United States.

Patients or healthcare providers who have received this product should contact their healthcare provider or the manufacturer for guidance. No illnesses or injuries have been reported in connection with this recall.

The recalled product

Product
fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2081-1
Manufacturer
Central Admixture Pharmacy Services Inc
Hazard
  • lack-of-sterility
  • infection-risk

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot: 17-275929
  • Exp. 10/12/2023

Distribution

Distributed nationwide across the United States.